Please login to the form below

Not currently logged in
Email:
Password:

Eisai expands reach of UK-based European business hub

Hatfield facility will now support the company's work in the Middle East and Africa

Eisai's European business centre in Hatfield in the UK is to take on additional responsibility for the company's operations in the Middle East and Africa.

The Japanese pharma company said the decision, which is expected to create a number of new jobs, underscores the importance it attaches to its UK presence.

Gary Hendler, Eisai EMEA president and CEO, said: "We chose to base our EMEA operations in the UK as we recognise the country's importance as a global hub for the pharmaceutical industry.

“Initiatives to support the life sciences sector championed by the Department of Business, Innovation and Skills (BIS) have added to our ability to cure and care for the health and wellbeing of more people across the EMEA region.”

In December the government launched its strategy for UK life sciences to help business grow by creating a 'life sciences ecosystem', attracting scientific talent to the country and promoting healthcare innovation.

The expansion of Eisai's £100m Hatfield facility, which opened in 2009,  is part of the company's plan to have a presence in the top 20 pharmaceutical market regions by 2015.

Gary Hendler said: "Eisai has been successfully operating in Europe for more than 20 years and we are deeply proud to be expanding our efforts to increase access to medicines based on a long-term sustainable strategy to improve affordability, availability and adoption.

“Our new UK-based EMEA hub will support these efforts, as well as improving knowledge interaction across the region, including shared pricing/reimbursement strategies and the transmission of medical and marketing knowledge."

20th March 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics